Samsara BioCapital’s CureVac CVAC Stock Holding History

Samsara BioCapital’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-95,318	Closed	-$8.72M	–	51
2021 Q1	$8.72M	Hold	95,318	–	–	1.61%	18
2020 Q4	$7.73K	Sell	95,318 -275,067	-74%	-$21.1M	0.78%	14
2020 Q3	$17.2M	Buy	+370,385	New	+$20.7M	4.81%	5

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Samsara BioCapital's CVAC Position: Q2 2021 in Review

Samsara BioCapital sold out of CureVac (CVAC) in Q2 2021, closing a stake of 95,318 shares — an estimated $8.72M sold.

Samsara BioCapital first reported a position in CVAC in Q3 2020 and held it in 3 quarters. The position peaked at $17.2M in Q3 2020. 109 funds tracked by Wall St. Rank hold CVAC as of Q2 2021.

Samsara BioCapital reported no remaining CureVac position as of Q2 2021 after selling out during the quarter.
Samsara BioCapital sold 95,318 CureVac shares in Q2 2021, an estimated $8.72M.
Samsara BioCapital first reported a position in CureVac in Q3 2020 and held it in 3 quarters.
Samsara BioCapital's CureVac position peaked at $17.2M in Q3 2020.
109 funds tracked by Wall St. Rank held CureVac as of Q2 2021.

Based on Samsara BioCapital's 13F filing for Q2 2021, filed 17 Aug 2021.